Cigna Investments Inc Vertex Pharmaceuticals Inc Transaction History

Cigna Investments Inc

  • $568 Million
  • Q3 2024

A detailed history of Cigna Investments Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cigna Investments Inc holds 2,671 shares of VRTX stock, worth $1.27 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
2,671
Previous 2,719 1.77%
Holding current value
$1.27 Million
Previous $1.28 Million 2.59%
% of portfolio
0.22%
Previous 0.24%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024
SELL
$460.0 - $505.78 $22,080 - $24,277
-48 Reduced 1.77%
2,671 $1.24 Million
Q2 2024

Jul 17, 2024
SELL
$392.81 - $485.53 $7,070 - $8,739
-18 Reduced 0.66%
2,719 $1.28 Million
Q1 2024

Apr 23, 2024
SELL
$407.69 - $446.08 $11,007 - $12,044
-27 Reduced 0.98%
2,737 $1.14 Million
Q4 2023

Jan 22, 2024
SELL
$343.0 - $410.68 $4,802 - $5,749
-14 Reduced 0.5%
2,764 $1.13 Million
Q3 2023

Oct 23, 2023
SELL
$338.18 - $362.46 $117,348 - $125,773
-347 Reduced 11.1%
2,778 $966,000
Q2 2023

Aug 01, 2023
SELL
$314.42 - $351.91 $314 - $351
-1 Reduced 0.03%
3,125 $1.1 Million
Q1 2023

May 11, 2023
SELL
$283.23 - $323.1 $17,843 - $20,355
-63 Reduced 1.98%
3,126 $985,000
Q4 2022

Feb 13, 2023
BUY
$285.76 - $321.48 $1,143 - $1,285
4 Added 0.13%
3,189 $921,000
Q3 2022

Nov 14, 2022
SELL
$273.83 - $305.53 $26,287 - $29,330
-96 Reduced 2.93%
3,185 $922,000
Q2 2022

Aug 15, 2022
SELL
$234.96 - $292.55 $283,831 - $353,400
-1,208 Reduced 26.91%
3,281 $925,000
Q1 2022

May 13, 2022
SELL
$221.42 - $260.97 $288,510 - $340,043
-1,303 Reduced 22.5%
4,489 $1.17 Million
Q4 2021

Feb 14, 2022
SELL
$177.01 - $223.45 $396,856 - $500,974
-2,242 Reduced 27.91%
5,792 $1.27 Million
Q3 2021

Nov 12, 2021
SELL
$181.39 - $202.99 $24,669 - $27,606
-136 Reduced 1.66%
8,034 $1.46 Million
Q2 2021

Aug 10, 2021
SELL
$187.49 - $221.1 $220,300 - $259,792
-1,175 Reduced 12.57%
8,170 $1.65 Million
Q1 2021

May 10, 2021
BUY
$207.02 - $241.31 $43,060 - $50,192
208 Added 2.28%
9,345 $2.01 Million
Q4 2020

Feb 11, 2021
BUY
$207.01 - $276.09 $151,117 - $201,545
730 Added 8.68%
9,137 $2.16 Million
Q3 2020

Nov 12, 2020
SELL
$255.65 - $303.1 $493,660 - $585,286
-1,931 Reduced 18.68%
8,407 $2.29 Million
Q2 2020

Aug 17, 2020
SELL
$225.48 - $295.8 $517,025 - $678,269
-2,293 Reduced 18.15%
10,338 $3 Million
Q1 2020

May 11, 2020
SELL
$199.77 - $247.81 $489,836 - $607,630
-2,452 Reduced 16.26%
12,631 $3.01 Million
Q4 2019

Feb 04, 2020
SELL
$166.71 - $223.91 $129,033 - $173,306
-774 Reduced 4.88%
15,083 $3.43 Million
Q3 2019

Nov 07, 2019
BUY
$166.23 - $187.09 $922,742 - $1.04 Million
5,551 Added 53.86%
15,857 $3.1 Million
Q2 2019

Aug 12, 2019
BUY
$164.61 - $190.37 $143,210 - $165,621
870 Added 9.22%
10,306 $1.72 Million
Q1 2019

May 10, 2019
SELL
$163.73 - $194.7 $89,724 - $106,695
-548 Reduced 5.49%
9,436 $1.74 Million
Q4 2018

Feb 06, 2019
BUY
$151.91 - $192.21 $2,430 - $3,075
16 Added 0.16%
9,984 $1.65 Million
Q3 2018

Nov 13, 2018
SELL
$167.73 - $192.74 $238,008 - $273,498
-1,419 Reduced 12.46%
9,968 $1.69 Million
Q2 2018

Aug 14, 2018
SELL
$145.72 - $169.96 $169,326 - $197,493
-1,162 Reduced 9.26%
11,387 $1.93 Million
Q1 2018

May 09, 2018
SELL
$151.6 - $177.13 $8,186 - $9,565
-54 Reduced 0.43%
12,549 $2.05 Million
Q4 2017

Jan 26, 2018
SELL
$137.28 - $155.55 $28,416 - $32,198
-207 Reduced 1.62%
12,603 $1.89 Million
Q3 2017

Oct 11, 2017
BUY
$148.13 - $162.24 $1.9 Million - $2.08 Million
12,810
12,810 $1.95 Million

Others Institutions Holding VRTX

# of Institutions
1,717
Shares Held
226M
Call Options Held
1.21M
Put Options Held
1.56M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cigna Investments Inc Portfolio

Follow Cigna Investments Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cigna Investments Inc , based on Form 13F filings with the SEC.

News

Stay updated on Cigna Investments Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email